Ranibizumab biosimilar - Senju Pharmaceutical

Drug Profile

Ranibizumab biosimilar - Senju Pharmaceutical

Alternative Names: SJP 0133

Latest Information Update: 30 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Senju Pharmaceutical
  • Class Eye disorder therapies; Monoclonal antibodies
  • Mechanism of Action Angiogenesis inhibitors; Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Age-related macular degeneration

Most Recent Events

  • 19 Oct 2017 Senju Pharmaceuticals plans a phase III trial for Age related macular degeneration in Japan (UMIN000030010)
  • 01 Oct 2017 Preclinical trials in Age-related macular degeneration in Japan (Intravitreous)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top